Skip to content
1887

Abstract

Coronavirus disease 2019 (COVID-19) pandemic has been prevailing for more than a year, associated with an increased number of opportunistic invasive fungal infections in patients who have been critically ill or immunocompromised. In this retrospective study, details of various clinical specimens received from suspected patients of fungal infections were studied. Fungal cultures were positive in 64% (51 out of 79) of COVID-19-positive patients and 43% (163 out of 381) of COVID-19-negative patients during the second wave of COVID-19 in 2021. Among COVID-19-infected patients, the most commonly isolated fungi were spp. (63%), followed by spp. (15%) and spp. (6%). The majority of samples that tested positive in COVID-19-infected patients were urine (17% from COVID-19-positive and 83% from COVID-19-negative patients), followed by serum (tested for galactomannan). isolation was observed in 27% (21/79) of urine samples and 15% (12/79) of respiratory samples [bronchoalveolar lavage (BAL), tracheal aspirate, and sputum] from COVID-19-positive patients. and were isolated from nasal and tissue samples in 6% of COVID-19-positive patients. There was an overall increase in fungal co-isolations during the COVID-19 pandemic (64% in COVID-19-positive and 43% in COVID-19-negative patients), which is a matter of great concern. The correlation of clinical symptomatology and laboratory isolation is important for the diagnosis and effective management of these patients.

  • This is an open-access article distributed under the terms of the Creative Commons Attribution License.
Loading

Article metrics loading...

/content/journal/acmi/10.1099/acmi.0.000640.v5
2025-01-29
2025-02-18
Loading full text...

Full text loading...

/deliver/fulltext/acmi/7/1/acmi000640.v5.html?itemId=/content/journal/acmi/10.1099/acmi.0.000640.v5&mimeType=html&fmt=ahah

References

  1. Mujeeb K, Adil Syed F, Alkhathlan Hamad Z, Tahir Muhammad N, Sadia S et al. COVID-19: a global challenge with old history, epidemiology and progress so far. Molecules 2020; 26:39 [View Article]
    [Google Scholar]
  2. Lai C-C, Wang C-Y, Hsueh P-R. Co-infections among patients with COVID-19: the need for combination therapy with non-anti-SARS-CoV-2 agents?. J Microbiol Immunol Infect 2020; 53:505–512 [View Article]
    [Google Scholar]
  3. Chen Z, John Wherry E. T cell responses in patients with COVID-19. Nat Rev Immunol 2020; 20:529–536 [View Article] [PubMed]
    [Google Scholar]
  4. Yang X, Yu Y, Xu J, Shu H, Xia J et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med 2020; 8:475–481 [View Article] [PubMed]
    [Google Scholar]
  5. Bhimraj A, Morgan RL, Shumaker AH, Lavergne V, Baden L et al. Infectious diseases society of America guidelines on the treatment and management of patients with COVID-19. Clin Infect Dis 2020ciaa478 [View Article] [PubMed]
    [Google Scholar]
  6. Song G, Liang G, Liu W. Fungal co-infections associated with global COVID-19 pandemic:a clinical and diagnostic perspective from China. Mycopathologia 2020; 185:599–606 [View Article] [PubMed]
    [Google Scholar]
  7. Rocha ICN, Hasan MM, Goyal S, Patel T, Jain S et al. COVID-19 and mucormycosis syndemic: double health threat to a collapsing healthcare system in India. Trop Med Int Health 2021; 26:1016–1018 [View Article] [PubMed]
    [Google Scholar]
  8. Alanio A, Dellière S, Fodil S, Bretagne S, Mégarbane B. Prevalence of putative invasive pulmonary aspergillosis in critically ill patients with COVID-19. Lancet Respir Med 2020; 8:e48–e49 [View Article]
    [Google Scholar]
  9. Arastehfar A, Carvalho A, van de Veerdonk FL, Jenks JD, Koehler P et al. COVID-19 Associated Pulmonary Aspergillosis (CAPA)-from immunology to treatment. J Fungi 2020; 6:91 [View Article] [PubMed]
    [Google Scholar]
  10. Brown L-AK, Ellis J, Gorton R, De S, Stone N. Surveillance for COVID-19-associated pulmonary aspergillosis. Lancet Microbe 2020; 1:e152 [View Article] [PubMed]
    [Google Scholar]
  11. Helleberg M, Steensen M, Arendrup MC. Invasive aspergillosis in patients with severe COVID-19 pneumonia. Clin Microbiol Infect 2021; 27:147–148 [View Article] [PubMed]
    [Google Scholar]
  12. Santana MF, Pivoto G, Alexandre MAA, Baía-da-Silva DC, Borba MG da S et al. Confirmed Invasive Pulmonary Aspergillosis and COVID-19: the value of postmortem findings to support antemortem management. Rev Soc Bras Med Trop 2020; 53:e20200401 [View Article]
    [Google Scholar]
  13. Rutsaert L, Steinfort N, Van Hunsel T, Bomans P, Naesens R et al. COVID-19-associated invasive pulmonary aspergillosis. Ann Intensive Care 2020; 10:71 [View Article] [PubMed]
    [Google Scholar]
  14. Chander J. Textbook of Medical Mycology JP Medical Ltd; 2018
    [Google Scholar]
  15. White PL, Dhillon R, Cordey A, Hughes H, Faggian F et al. A national strategy to diagnose coronavirus disease 2019-associated invasive fungal disease in the intensive care unit. Clin Infect Dis 2021; 73:e1634–e1644 [View Article] [PubMed]
    [Google Scholar]
  16. Chen N, Zhou M, Dong X, Qu J, Gong F et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020; 395:507–513 [View Article] [PubMed]
    [Google Scholar]
  17. Bhatt K, Agolli A, Patel MH, Garimella R, Devi M et al. High mortality co-infections of COVID-19 patients: mucormycosis and other fungal infections. Discoveries 2021; 9:e126 [View Article] [PubMed]
    [Google Scholar]
  18. Zhu X, Ge Y, Wu T, Zhao K, Chen Y et al. Co-infection with respiratory pathogens among COVID-2019 cases. Virus Res 2020; 285:198005 [View Article] [PubMed]
    [Google Scholar]
  19. Lewis WP, Rishi D, Alan C, Harriet H, Federica F et al. A national strategy to diagnose COVID-19 associated invasive fungal disease in the ICU. Clin Infect Dis 2021; 73:e1634–e1644 [View Article]
    [Google Scholar]
  20. Mastrangelo A, Germinario BN, Ferrante M, Frangi C, Li Voti R et al. Candidemia in coronavirus disease 2019 (COVID-19) patients: Incidence and characteristics in a prospective cohort compared with historical non-COVID-19 controls. Clin Infect Dis 2021; 73:e2838–e2839 [View Article]
    [Google Scholar]
  21. Nucci M, Barreiros G, Guimarães LF, Deriquehem VAS, Castiñeiras AC et al. Increased incidence of candidemia in a tertiary care hospital with the COVID-19 pandemic. Mycoses 2021; 64:152–156 [View Article] [PubMed]
    [Google Scholar]
  22. Macauley P, Epelbaum O. Epidemiology and mycology of candidaemia in non-oncological medical intensive care unit patients in a tertiary center in the United States: overall analysis and comparison between non-COVID-19 and COVID-19 cases. Mycoses 2021; 64:634–640 [View Article] [PubMed]
    [Google Scholar]
  23. Martins AC, Psaltikidis EM, de Lima TC, Fagnani R, Schreiber AZ et al. COVID-19 and invasive fungal coinfections: a case series at a Brazilian referral hospital. J Mycol Med 2021; 31:101175 [View Article] [PubMed]
    [Google Scholar]
  24. Hughes S, Troise O, Donaldson H, Mughal N, Moore LSP. Bacterial and fungal coinfection among hospitalized patients with COVID-19: a retrospective cohort study in a UK secondary-care setting. Clin Microbiol Infect 2020; 26:1395–1399 [View Article] [PubMed]
    [Google Scholar]
  25. Muthu V, Rudramurthy SM, Chakrabarti A, Agarwal R. Epidemiology and pathophysiology of COVID-19-associated mucormycosis: India versus the rest of the world. Mycopathologia 2021; 186:739–754 [View Article] [PubMed]
    [Google Scholar]
  26. Garg D, Muthu V, Sehgal IS, Ramachandran R, Kaur H et al. Coronavirus disease (COVID-19) associated mucormycosis (CAM): case report and systematic review of literature. Mycopathologia 2021; 186:289–298 [View Article]
    [Google Scholar]
  27. Nehara HR, Puri I, Singhal V, Ih S, Bishnoi BR et al. Rhinocerebral mucormycosis in COVID-19 patient with diabetes a deadly trio: Case series from the north-western part of India. Indian J Med Microbiol 2021; 39:380–383 [View Article] [PubMed]
    [Google Scholar]
  28. Bellanger AP, Navellou JC, Lepiller Q, Brion A, Brunel AS et al. Mixed mold infection with Aspergillus fumigatus and Rhizopus microsporus in a severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) patient. Infect Dis Now 2021; 51:633–635 [View Article] [PubMed]
    [Google Scholar]
  29. John TM, Jacob CN, Kontoyiannis DP. When uncontrolled diabetes mellitus and severe COVID-19 converge: the perfect storm for mucormycosis. J Fungi 2021; 7:298 [View Article] [PubMed]
    [Google Scholar]
  30. Slavin M, van Hal S, Sorrell TC, Lee A, Marriott DJ et al. Invasive infections due to filamentous fungi other than Aspergillus: epidemiology and determinants of mortality. Clin Microbiol Infect 2015; 21:490 [View Article] [PubMed]
    [Google Scholar]
/content/journal/acmi/10.1099/acmi.0.000640.v5
Loading
/content/journal/acmi/10.1099/acmi.0.000640.v5
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error